(Q45256831)

11 December 2017

title

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study (English)

1 reference

11 December 2017

main subject

phase II clinical trial

0 references

1 reference

Rudolph M Navari

1

1 reference

11 December 2017

Lawrence H Einhorn

2

1 reference

11 December 2017

Steven D Passik

3

1 reference

11 December 2017

Patrick J Loehrer

4

1 reference

11 December 2017

Cynthia Johnson

5

1 reference

11 December 2017

M L Mayer

6

1 reference

11 December 2017

J McClean

7

1 reference

11 December 2017

Jake Vinson

8

1 reference

11 December 2017

W Pletcher

9

1 reference

11 December 2017

publication date

8 February 2005

1 reference

Supportive Care in Cancer

11 December 2017

published in

1 reference

11 December 2017

volume

13

1 reference

11 December 2017

issue

7

1 reference

11 December 2017

page(s)

529-534

1 reference

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

11 December 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-004-0755-6

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

12 December 2020

Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

1 reference

12 December 2020

Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer

1 reference

12 December 2020

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine

1 reference

12 December 2020

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

12 December 2020

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

1 reference

12 December 2020

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

Olanzapine for intractable nausea in palliative care patients

1 reference

12 December 2020

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study

1 reference

12 December 2020

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

12 December 2020

Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists

1 reference

12 December 2020

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

12 December 2020

Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

12 December 2020

Why Do We Need Another Antiemetic? Just Ask

1 reference

12 December 2020

Radioreceptor binding profile of the atypical antipsychotic olanzapine

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

A Retrospective Chart Review of the Use of Olanzapine for the Prevention of Delayed Emesis in Cancer Patients

1 reference

12 December 2020

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

12 December 2020

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

1 reference

12 December 2020

Do we need new antiemetic guidelines?

1 reference

12 December 2020

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain

1 reference

12 December 2020

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report

1 reference

12 December 2020

10.1007/S00520-004-0755-6

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1027216213

0 references

1 reference